In today’s session SAGE Therapeutics Inc (SAGE) registered an unusually high (950) contracts volume of call trades. Someone, most probably a professional was a very active buyer of the November, 2016 call, expecting serious SAGE increase. With 950 contracts traded and 6234 open interest for the Nov, 16 contract, it seems this is a quite bullish bet. The option with symbol: SAGE161118C00040000 closed last at: $5.3 or 7% down. About 42,844 shares traded hands. SAGE Therapeutics Inc (NASDAQ:SAGE) has risen 40.40% since March 29, 2016 and is uptrending. It has outperformed by 36.93% the S&P500.
Analysts await SAGE Therapeutics Inc (NASDAQ:SAGE) to report earnings on November, 3. They expect $-1.11 EPS, down 32.14% or $0.27 from last year’s $-0.84 per share. After $-1.08 actual EPS reported by SAGE Therapeutics Inc for the previous quarter, Wall Street now forecasts 2.78% negative EPS growth.
SAGE Therapeutics Inc (NASDAQ:SAGE) Ratings Coverage
Out of 9 analysts covering SAGE Therapeutics (NASDAQ:SAGE), 7 rate it a “Buy”, 1 “Sell”, while 1 “Hold”. This means 78% are positive. $90 is the highest target while $18 is the lowest. The $65.71 average target is 51.16% above today’s ($43.47) stock price. SAGE Therapeutics has been the topic of 10 analyst reports since September 3, 2015 according to StockzIntelligence Inc. The stock has “Outperform” rating given by BMO Capital Markets on Wednesday, June 29. Goldman Sachs initiated it with “Neutral” rating and $83 target price in Wednesday, March 30 report. The company was initiated on Friday, March 11 by Lake Street. The firm earned “Buy” rating on Thursday, September 3 by Leerink Swann. As per Thursday, June 23, the company rating was initiated by H.C. Wainwright. The rating was initiated by Chardan Capital Markets on Tuesday, May 24 with “Sell”. The company was initiated on Tuesday, September 13 by Raymond James. The firm earned “Buy” rating on Thursday, September 3 by JP Morgan.
According to Zacks Investment Research, “SAGE Therapeutics Inc. is a biopharmaceutical company developing and commercializing medicines to treat life-threatening central nervous system (CNS) disorders. The Company provides treatments for schizophrenia, major depressive disorder, pain, and traumatic brain injury conditions. Its initial product candidates include SAGE-547, SAGE-689 and SAGE-217. SAGE Therapeutics, Inc. is based in Cambridge, Massachusetts.”
Insitutional Activity: The institutional sentiment decreased to 1.51 in Q2 2016. Its down 0.73, from 2.24 in 2016Q1. The ratio fall, as 28 funds sold all SAGE Therapeutics Inc shares owned while 27 reduced positions. 23 funds bought stakes while 60 increased positions. They now own 29.30 million shares or 2.83% more from 28.49 million shares in 2016Q1.
Baker Bros Advisors Limited Partnership has invested 0.07% of its portfolio in SAGE Therapeutics Inc (NASDAQ:SAGE). Parametric Associates Limited Liability last reported 17,686 shares in the company. Moreover, Oxford Asset has 0.22% invested in SAGE Therapeutics Inc (NASDAQ:SAGE) for 172,485 shares. Harvey Management holds 0.23% of its portfolio in SAGE Therapeutics Inc (NASDAQ:SAGE) for 15,545 shares. Proshare Ltd holds 0.01% of its portfolio in SAGE Therapeutics Inc (NASDAQ:SAGE) for 27,110 shares. Blackrock Inc reported 17,064 shares or 0% of all its holdings. Wfg Advsrs Lp last reported 156 shares in the company. Eagle Asset Mngmt holds 0.18% of its portfolio in SAGE Therapeutics Inc (NASDAQ:SAGE) for 873,924 shares. Palo Alto Investors Ltd Liability Co last reported 0.95% of its portfolio in the stock. Voya Inv Management Ltd Liability has 0.03% invested in the company for 359,813 shares. The Connecticut-based Great Point Prns Llc has invested 2.85% in SAGE Therapeutics Inc (NASDAQ:SAGE). Brown Brothers Harriman And has invested 0% of its portfolio in SAGE Therapeutics Inc (NASDAQ:SAGE). Bessemer Gp holds 0.01% or 32,828 shares in its portfolio. Commercial Bank Of America De reported 67,302 shares or 0% of all its holdings. Schwab Charles Invest Inc has 71,041 shares for 0% of their US portfolio.
Insider Transactions: Since May 16, 2016, the stock had 0 insider buys, and 5 insider sales for $54.36 million net activity. IGUCHI KIMI sold $247,750 worth of stock. The insider STARR KEVIN P sold $26.56 million. $26.56 million worth of SAGE Therapeutics Inc (NASDAQ:SAGE) was sold by Third Rock Ventures II – L.P.. On Tuesday, July 12 Robichaud Albert sold $880,000 worth of the stock or 22,000 shares.
SAGE Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The company has a market cap of $1.58 billion. The Firm is engaged in developing and commercializing medicines to treat central nervous system disorders. It currently has negative earnings. The Company’s lead product candidate, SAGE-547 is an intravenous formulation of allopregnanolone, a neurosteroid that acts as a synaptic and extrasynaptic modulator of the GABAA receptor.
SAGE Company Profile
SAGE Therapeutics, Inc., incorporated on April 16, 2010, is a clinical-stage biopharmaceutical company. The Firm is engaged in developing and commercializing medicines to treat central nervous system (CNS) disorders. The Company’s lead product candidate, SAGE-547 is an intravenous formulation of allopregnanolone, a neurosteroid that acts as a synaptic and extrasynaptic modulator of the GABAA receptor. The Company’s next-generation product candidates, SAGE-217 and SAGE-689, also targets the GABAA receptor system. The Firm is focused on developing drugs based on selective allosteric modulation of CNS synaptic and extrasynaptic receptors. The Company’s chemistry platform is focused on chemical scaffolds of endogenous or chemically modified synthetic neuroactive steroid compounds that are allosteric modulators of GABAA or N-Methyl-D-aspartic acid or N-Methyl-D-aspartate (NMDA) receptors.
More notable recent SAGE Therapeutics Inc (NASDAQ:SAGE) news were published by: Fool.com which released: “Here’s Why SAGE Therapeutics Inc. Is Surging Today” on July 12, 2016, also Prnewswire.com with their article: “Sage Therapeutics, Inc. – Product Pipeline Review – 2016” published on September 27, 2016, Marketwatch.com published: “Sage Therapeutics stock rises 12% after FDA designates drug a ‘breakthrough …” on September 06, 2016. More interesting news about SAGE Therapeutics Inc (NASDAQ:SAGE) were released by: Valuewalk.com and their article: “SAGE Therapeutics Inc (SAGE) – Debunking Asclepia Capital” published on April 01, 2016 as well as Valuewalk.com‘s news article titled: “SAGE Therapeutics Inc (SAGE) Overhyped Lead Drug Headed for Failure â€“ Kerrisdale” with publication date: March 23, 2016.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.